secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liminatus Pharma, Inc. (LIMN)
CIK:        0001971387
Form:       8-K
Filed at:   2025-08-25T23:59:59+00:00
Accession:  0001104659-25-082579
Event type: regulatory
Sentiment:  negative
Materiality: 0.55
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liminatus Pharma receives Nasdaq delinquency notice for late Q2 10-Q filing; has 60 days to submit compliance plan
--------------------------------------------------------------------------------

- Nasdaq notified Liminatus on Aug 22, 2025 of non-compliance with Listing Rule 5250(c)(1) due to delayed Form 10-Q for period ended June 30, 2025.
- Company has 60 days, until Oct 21, 2025, to submit a plan to regain compliance; Nasdaq may grant extension to Feb 16, 2026 if plan accepted.
- Common stock (LIMN) continues to trade on Nasdaq; no immediate delisting effect.
- Liminatus is a pre-clinical stage biopharma developing immune-modulating cancer therapies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971387/000110465925082579/0001104659-25-082579-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971387/000110465925082579/tm2524293d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-082579

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer